Vaneck Etf Profile

Vaneck Biotech is trading at 215.91 as of the 28th of September 2021. This is a -0.04 percent down since the beginning of the trading day. The etf's open price was 216.0. Equity ratings for Vaneck Biotech ETF are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of August 2021 and ending today, the 28th of September 2021. Click here to learn more.

Vaneck Biotech Etf Profile

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Biotech 25 Index. Biotech Vaneck is traded on NYSEArca Exchange in the United States. more on Vaneck Biotech
Vaneck Biotech ETF is not yet fully synchronised with the market data
Vaneck Biotech ETF is unlikely to experience financial distress in the next 2 years
The fund holds 99.99% of its assets under management (AUM) in equities
Legal NameVaneck Biotech ETF
ChairmanPhilip Hornig  (View All)
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Vaneck Biotech's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Not RatedFairly Valued
IssuerVan Eck
DescriptionVanEck Biotech ETF
Inception Date2011-12-20
BenchmarkMarket Vectors US Listed Biotech 25 Index
Entity TypeRegulated Investment Company
Asset Under Management615.98 Million
Average Trading Valume14,195
Asset TypeEquity
FocusHealth Care
Market ConcentrationDeveloped Markets
AdministratorVan Eck Associates Corporation
AdvisorVan Eck Associates Corporation
CustodianState Street Bank and Trust Company
DistributorVan Eck Securities Corporation
Portfolio ManagerHao-Hung Peter Liao, Guo Hua Jason Jin
Transfer AgentState Street Bank and Trust Company
Fiscal Year End31-Oct
Number of Constituents26.0
Total Expense0.39
Management Fee0.35
Average Daily Volume In Three Month15.17k
Average Daily Volume Last 10 Day13.89k
Vaneck Biotech ETF [BBH] is traded in USA and was established 2011-12-20. The fund is classified under Health category within VanEck family. Vaneck Biotech ETF currently have 574.36 M in assets under management (AUM). , while the total return for the last 3 years was 19.37%.
Check Vaneck Biotech Probability Of Bankruptcy

Top Vaneck Biotech ETF Constituents

Vaneck Biotech Target Price Odds Analysis

What are Vaneck Biotech's target price odds to finish over the current price? In reference to a normal probability distribution, the odds of Vaneck Biotech jumping above the current price in 90 days from now is about 18.25%. The Vaneck Biotech ETF probability density function shows the probability of Vaneck Biotech etf to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon Vaneck Biotech has a beta of 0.0784 suggesting as returns on the market go up, Vaneck Biotech average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Vaneck Biotech ETF will be expected to be much smaller as well. Additionally, the company has an alpha of 0.144, implying that it can generate a 0.14 percent excess return over DOW after adjusting for the inherited market risk (beta).
 Odds Down 215.91HorizonTargetOdds Up 215.91 
81.54%90 days
Based on a normal probability distribution, the odds of Vaneck Biotech to move above the current price in 90 days from now is about 18.25 (This Vaneck Biotech ETF probability density function shows the probability of Vaneck Etf to fall within a particular range of prices over 90 days) .

Vaneck Biotech Major Institutional Holders

Institutional Holdings refers to the ownership stake in Vaneck Biotech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Vaneck Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Vaneck Biotech's value.
InstituionSecurity TypeTotal SharesValue
Group One Trading LpCall Options3.8 M130.8 M
Group One Trading LpPut Options3.3 M111.7 M
Goldman Sachs Group IncFund Units116.6 K23.5 M
View Vaneck Biotech Diagnostics

Vaneck Biotech ETF Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Vaneck Biotech market risk premium is the additional return an investor will receive from holding Vaneck Biotech long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Vaneck Biotech. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Vaneck Biotech's alpha and beta are two of the key measurements used to evaluate Vaneck Biotech's performance over the market, the standard measures of volatility play an important role as well.

Vaneck Biotech Against Markets

Picking the right benchmark for Vaneck Biotech etf is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Vaneck Biotech etf price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Vaneck Biotech is critical whether you are bullish or bearish towards Vaneck Biotech ETF at a given time.

View Currently Related Equities

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Vaneck Biotech etf to make a market-neutral strategy. Peer analysis of Vaneck Biotech could also be used in its relative valuation, which is a method of valuing Vaneck Biotech by comparing valuation metrics with similar companies.
Continue to Trending Equities. Note that the Vaneck Biotech ETF information on this page should be used as a complementary analysis to other Vaneck Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Probability Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Complementary Tools for Vaneck Etf analysis

When running Vaneck Biotech ETF price analysis, check to measure Vaneck Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaneck Biotech is operating at the current time. Most of Vaneck Biotech's value examination focuses on studying past and present price action to predict the probability of Vaneck Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Vaneck Biotech's price. Additionally, you may evaluate how the addition of Vaneck Biotech to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
The market value of Vaneck Biotech ETF is measured differently than its book value, which is the value of Vaneck that is recorded on the company's balance sheet. Investors also form their own opinion of Vaneck Biotech's value that differs from its market value or its book value, called intrinsic value, which is Vaneck Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vaneck Biotech's market value can be influenced by many factors that don't directly affect Vaneck Biotech ETF underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vaneck Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Vaneck Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vaneck Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.